A rare disease policy shift just landed at the WHO. Could it change hemophilia care worldwide?
Find out how the WHO hemophilia resolution could reshape diagnosis, treatment access, prophylaxis and bleeding disorder care worldwide.
Why Star Therapeutics’ FDA win for VGA039 could reshape the von Willebrand disease treatment race.
Star Therapeutics won dual FDA designations for VGA039 in von Willebrand disease. Read what it could change, and what still needs proving.